A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty, EMPRISE, real-world study on effectiveness shows that Jardiance was associated with a decreased risk of hospitalization for heart failure and a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors and GLP-1 receptor agonists. The interim analysis included 190,000 adults in the U.S. with type 2 diabetes with and without cardiovascular disease. The results were shared on behalf of Boehringer Ingelheim and Eli Lilly and Company (LLY) at the American Heart Association Scientific Sessions 2019 in Philadelphia.

Boeing and Biman Bangladesh Airlines announced at the 2019 Dubai Airshow that the carrier is expanding its 787 Dreamliner fleet with two additional airplanes valued at $585M at list prices. The purchase - recorded in October as an unidentified order on Boeing's website - complements Biman's fleet of 787-8 jets with the larger and longer-range 787-9 variant.

Caladrius Biosciences presented results from the ESCaPE-CMD trial of Caladrius's autologous CD34+ cell therapy, CLBS16, at the American Heart Association Scientific Sessions 2019. Data showed highly statistically significant improvement in coronary flow reserve correlating with symptom relief for patients with coronary microvascular dysfunction after a single intracoronary injection of CLBS16. The results for patients who have completed the six-month follow-up to date were presented, with the results from the remaining patients expected by the end of 2019. "CLB16 represents a potential breakthrough for the treatment of CMD, a condition that affects millions in the U.S. and that disproportionately afflicts women. This is the first time that a therapy has shown the ability to durably increase coronary flow reserve and potentially reverse CMD after a single dose. These reported results clearly support the premise that manageable cell-based tissue regeneration is possible in patients with CMD," said David Mazzo, CEO of Caladrius. "The reported results from the ESCaPE-CMD trial bring us one step closer to realizing the promise of CD34+ cell therapy to augment microvasculature in the heart enabling the restoration of health rather than simply management of disease."

The Medicines Company announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol, or LDL-C, lowering Phase 3 clinical studies of inclisiran, an investigational twice-yearly therapy to reduce LDL-C and the first and only cholesterol-lowering treatment in the siRNA class. In ORION-10, twice-yearly dosing with inclisiran sodium 300 mg met all primary and secondary efficacy endpoints, was well-tolerated and again demonstrated an excellent safety profile. Full study results were presented during a late-breaking science session at the American Heart Association, or AHA, Scientific Sessions in Philadelphia. "Cumulative exposure to high LDL-C levels presents a significant risk of future heart attacks and strokes for millions of people, particularly those with ASCVD," said study principal investigator R. Scott Wright, M.D., Professor of Medicine, Consultant in Cardiology, Mayo Clinic in Rochester, Minnesota. "The data from ORION-10 show that inclisiran lowers LDL-C significantly and sustains reductions over a six-month period with a safety profile similar to placebo."

CN said that the Teamsters Canadian Rail Conference - Conductors, Trainpersons and Yardpersons, or TCRC-CTY, which represents approximately 3,200 CN employees who work as train conductors and railyard coordinators only in Canada, has given the company a 72-hour notice of its intention to strike as of 00:01 hours Eastern Standard Time on November 19. Rob Reilly, executive VP and COO of CN, said: "We continue to negotiate in good faith to reach a fair agreement before the strike deadline. In the spirit of protecting the Canadian economy, we have offered the union binding arbitration and they have declined. If a settlement cannot be reached this weekend, we will once again encourage the union leadership to accept binding arbitration as an alternative to disrupting the Canadian economy. We remain committed to constructive talks to reach an agreement without a work stoppage."

Bristol-Myers Squibb Company (BMY) announced that it currently expects there will be no further extension of the expiration date of the offers to exchange notes issued by Celgene Corporation (CELG) for up to $19.85B aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene notes. As previously announced, the exchange offers and consent solicitations are currently scheduled to expire on November 20. The closing of the merger is expected to occur on November 20. As a result, Bristol-Myers Squibb currently expects that there will be no further extension of the expiration date as it is anticipated that the merger will be completed on the expiration date. The settlement date for the exchange offers is expected to occur on November 22, 2019.